Search research articles
Contact Us
Filters
Showing results (401-410 of 565) with videos related to
Page
of 57
Sort By:
Pharmacogenetics and Genomics
|
December 31, 2010
CYP2C19 variation and citalopram response
David A Mrazek, Joanna M Biernacka, Dennis J O'Kane, et al.
Journal of Psychiatric Research
|
April 8, 2018
A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder
Katherine Sanchez, Michael O Killian, Taryn L Mayes, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 18, 2024
Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder
Sudeepa Bhattacharyya, Siamak MahmoudianDehkordi, Matthew J Sniatynski, et al.
Psychological Medicine
|
February 9, 2005
Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D
Maurizio Fava, Jonathan E Alpert, Cheryl N Carmin, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
|
March 4, 2010
Health-related quality of life in depression: a STAR*D report
Ella J Daly, Madhukar H Trivedi, Stephen R Wisniewski, et al.
The Journal of Clinical Psychiatry
|
February 5, 2009
Family history of depression and therapeutic outcome: findings from STAR*D
Mustafa M Husain, A John Rush, Stephen R Wisniewski, et al.
Molecular Cell
|
September 13, 2011
Systematic and quantitative assessment of the ubiquitin-modified proteome
Woong Kim, Eric J Bennett, Edward L Huttlin, et al.
The Australian and New Zealand Journal of Psychiatry
|
November 6, 2023
Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: II. Sensitivity to treatment effects
Scott T Aaronson, Harold A Sackeim, Mei Jiang, et al.
The American Journal of Psychiatry
|
April 3, 2009
Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report
Stephen R Wisniewski, A John Rush, Andrew A Nierenberg, et al.
Neuron
|
December 13, 2005
Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16
Zhifeng Zhou, Eric J Peters, Steven P Hamilton, et al.
Page
of 57
Search research articles
Search
Showing results (401-410 of 565) with videos related to
Sort By:
Page
of 57
Pharmacogenetics and Genomics
|
December 31, 2010
CYP2C19 variation and citalopram response
David A Mrazek, Joanna M Biernacka, Dennis J O'Kane, et al.
Journal of Psychiatric Research
|
April 8, 2018
A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder
Katherine Sanchez, Michael O Killian, Taryn L Mayes, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 18, 2024
Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder
Sudeepa Bhattacharyya, Siamak MahmoudianDehkordi, Matthew J Sniatynski, et al.
Psychological Medicine
|
February 9, 2005
Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D
Maurizio Fava, Jonathan E Alpert, Cheryl N Carmin, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
|
March 4, 2010
Health-related quality of life in depression: a STAR*D report
Ella J Daly, Madhukar H Trivedi, Stephen R Wisniewski, et al.
The Journal of Clinical Psychiatry
|
February 5, 2009
Family history of depression and therapeutic outcome: findings from STAR*D
Mustafa M Husain, A John Rush, Stephen R Wisniewski, et al.
Molecular Cell
|
September 13, 2011
Systematic and quantitative assessment of the ubiquitin-modified proteome
Woong Kim, Eric J Bennett, Edward L Huttlin, et al.
The Australian and New Zealand Journal of Psychiatry
|
November 6, 2023
Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: II. Sensitivity to treatment effects
Scott T Aaronson, Harold A Sackeim, Mei Jiang, et al.
The American Journal of Psychiatry
|
April 3, 2009
Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report
Stephen R Wisniewski, A John Rush, Andrew A Nierenberg, et al.
Neuron
|
December 13, 2005
Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16
Zhifeng Zhou, Eric J Peters, Steven P Hamilton, et al.
Page
of 57